DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations
DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations
DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P., a North-American focused private equity firm.
DURECt 公司（纳斯达克：DRRX）是一家处于后期阶段的生物制药公司，正在开创表观遗传疗法的开发，以改变严重和危及生命的疾病，如急性器官损伤的治疗。今天宣布将其 ALZEt 系列渗透泵出售给 Lafayette Instrument Co.（LIC），该公司是 Branfod Castle Partners II, L.P. 的投资组合公司，专注于北美的股权投资。
) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer." alt="DURECT Corporation () is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer.">
) 是一家处于后期阶段的生物制药公司，正在开创针对失调的 DNA 甲基化的表观遗传疗法，以改变严重和危及生命的疾病的治疗，包括急性器官损伤和癌症。" alt="DURECt 公司（）是一家处于后期阶段的生物制药公司，正在开创针对失调的 DNA 甲基化的表观遗传疗法，以改变严重和危及生命的疾病的治疗，包括急性器官损伤和癌症。"
Under the terms of the agreement, LIC paid DURECT $17.5 million in exchange for certain assets and liabilities associated with the ALZET product line. Simultaneous with this transaction, DURECT has paid off all remaining obligations under the term loan agreement with Oxford Finance LLC.
根据协议条款，LIC 向 DURECt 支付了1750万美国美元，以换取与 ALZEt 产品线相关的某些资产和负债。与此交易同时进行，DURECt 已经偿还了与 Oxford Finance LLC 签订的定期贷款协议下所有剩余的义务。
